(AZN) AstraZeneca - Overview

Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NASDAQ (USA) | Market Cap: 315.467m USD | Total Return: 60.1% in 12m

Oncology, Respiratory, Cardiovascular, Vaccines, Rare Diseases
Total Rating 67
Safety 69
Buy Signal 0.31
Drug Manufacturers - General
Industry Rotation: -2.2
Market Cap: 315B
Avg Turnover: 349M USD
ATR: 2.35%
Peers RS (IBD): 56.2
Risk 5d forecast
Volatility24.4%
Rel. Tail Risk-3.95%
Reward TTM
Sharpe Ratio1.72
Alpha38.37
Character TTM
Beta0.296
Beta Downside0.446
Drawdowns 3y
Max DD27.87%
CAGR/Max DD0.50
EPS (Earnings per Share) EPS (Earnings per Share) of AZN over the last years for every Quarter: "2021-03": 1.1835, "2021-06": 0.4173, "2021-09": -1.1043, "2021-12": -0.2243, "2022-03": 0.2473, "2022-06": 0.2308, "2022-09": 1.052, "2022-12": 0.5779, "2023-03": 1.1558, "2023-06": 1.1654, "2023-09": 0.8808, "2023-12": 0.615, "2024-03": 1.3968, "2024-06": 1.2353, "2024-09": 0.9149, "2024-12": 1.045, "2025-03": 1.245, "2025-06": 1.085, "2025-09": 1.19, "2025-12": null,
EPS CAGR: 103.99%
EPS Trend: 71.9%
Qual. Beats: 0
Revenue Revenue of AZN over the last years for every Quarter: 2021-03: 7320, 2021-06: 8220, 2021-09: 9866, 2021-12: 12011, 2022-03: 11390, 2022-06: 10771, 2022-09: 10982, 2022-12: 11207, 2023-03: 10879, 2023-06: 11416, 2023-09: 11492, 2023-12: 12024, 2024-03: 12679, 2024-06: 12938, 2024-09: 13565, 2024-12: 14891, 2025-03: 13588, 2025-06: 14457, 2025-09: 15191, 2025-12: 15503,
Rev. CAGR: 8.57%
Rev. Trend: 94.7%
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: AZN AstraZeneca

AstraZeneca PLC (NASDAQ: AZN) is a global biopharmaceutical leader headquartered in Cambridge, UK, dedicated to discovering, developing, manufacturing, and commercializing prescription medicines across oncology, cardiovascular-renal-metabolism, respiratory-immunology, vaccines, and rare diseases.

The company’s extensive portfolio includes blockbuster oncology agents such as Tagrisso, Imfinzi, Lynparza and Enhertu, as well as leading cardiovascular and metabolic drugs like Farxiga, Crestor, and Brilinta, plus respiratory products such as Symbicort and Fasenra. AstraZeneca reaches physicians worldwide through a network of distributors and local offices spanning the UK, the Americas, Europe, Asia, Africa and Australasia.

In its latest Q2-2024 results, AstraZeneca reported revenue of $13.2 billion, a 9 % year-over-year increase driven primarily by strong oncology sales, and an R&D spend of $5.5 billion, underscoring its commitment to pipeline growth. The firm’s dividend yield sits near 3.2 % and its market-cap exceeds $180 billion, while sector-wide drivers such as an aging global population and rising demand for specialty biologics continue to boost growth prospects.

For a deeper dive into valuation metrics and forward-looking insights, consider exploring ValueRay’s analyst tools.

Headlines to Watch Out For
  • New oncology drug approvals drive revenue growth
  • Pipeline success in rare diseases expands market share
  • Global economic slowdown impacts prescription drug demand
  • Increased R&D costs pressure profit margins
  • Regulatory hurdles delay key drug launches
Piotroski VR‑10 (Strict) 7.0
Net Income: 10.22b TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.27 > 1.0
NWC/Revenue: -3.22% < 20% (prev -3.77%; Δ 0.55% < -1%)
CFO/TA 0.13 > 3% & CFO 14.66b > Net Income 10.22b
Net Debt (23.99b) to EBITDA (19.83b): 1.21 < 3
Current Ratio: 0.94 > 1.5 & < 3
Outstanding Shares: last quarter (781.0m) vs 12m ago 0.0% < -2%
Gross Margin: 81.90% > 18% (prev 0.81%; Δ 8.11k% > 0.5%)
Asset Turnover: 53.86% > 50% (prev 51.98%; Δ 1.89% > 0%)
Interest Coverage Ratio: 8.32 > 6 (EBITDA TTM 19.83b / Interest Expense TTM 1.69b)
Altman Z'' 1.29
A: -0.02 (Total Current Assets 28.72b - Total Current Liabilities 30.62b) / Total Assets 114.07b
B: 0.10 (Retained Earnings 10.97b / Total Assets 114.07b)
C: 0.13 (EBIT TTM 14.10b / Avg Total Assets 109.05b)
D: 0.21 (Book Value of Equity 13.40b / Total Liabilities 65.36b)
Altman-Z'' Score: 1.29 = BB
Beneish M -2.97
DSRI: 1.08 (Receivables 15.18b/12.97b, Revenue 58.74b/54.07b)
GMI: 0.99 (GM 81.90% / 81.12%)
AQI: 0.97 (AQ_t 0.62 / AQ_t-1 0.64)
SGI: 1.09 (Revenue 58.74b / 54.07b)
TATA: -0.04 (NI 10.22b - CFO 14.66b) / TA 114.07b)
Beneish M-Score: -2.97 (Cap -4..+1) = A
What is the price of AZN shares? As of April 09, 2026, the stock is trading at USD 204.27 with a total of 1,700,592 shares traded.
Over the past week, the price has changed by +1.76%, over one month by +4.78%, over three months by +9.79% and over the past year by +60.13%.
Is AZN a buy, sell or hold? AstraZeneca has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy AZN.
  • StrongBuy: 6
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AZN price?
Analysts Target Price 208.8 2.2%
AstraZeneca (AZN) - Fundamental Data Overview as of 04 April 2026
P/E Trailing = 31.1623
P/E Forward = 19.2678
P/S = 5.3707
P/B = 6.1782
P/EG = 1.6465
Revenue TTM = 58.74b USD
EBIT TTM = 14.10b USD
EBITDA TTM = 19.83b USD
Long Term Debt = 24.71b USD (from longTermDebt, last quarter)
Short Term Debt = 3.57b USD (from shortTermDebt, last quarter)
Debt = 29.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.99b USD (from netDebt column, last quarter)
Enterprise Value = 339.46b USD (315.47b + Debt 29.70b - CCE 5.71b)
Interest Coverage Ratio = 8.32 (Ebit TTM 14.10b / Interest Expense TTM 1.69b)
EV/FCF = 32.11x (Enterprise Value 339.46b / FCF TTM 10.57b)
FCF Yield = 3.11% (FCF TTM 10.57b / Enterprise Value 339.46b)
FCF Margin = 18.00% (FCF TTM 10.57b / Revenue TTM 58.74b)
Net Margin = 17.41% (Net Income TTM 10.22b / Revenue TTM 58.74b)
Gross Margin = 81.90% ((Revenue TTM 58.74b - Cost of Revenue TTM 10.63b) / Revenue TTM)
Gross Margin QoQ = 79.89% (prev 81.56%)
Tobins Q-Ratio = 2.98 (Enterprise Value 339.46b / Total Assets 114.07b)
Interest Expense / Debt = 1.59% (Interest Expense 472.0m / Debt 29.70b)
Taxrate = 11.41% (300.0m / 2.63b)
NOPAT = 12.49b (EBIT 14.10b * (1 - 11.41%))
Current Ratio = 0.94 (Total Current Assets 28.72b / Total Current Liabilities 30.62b)
Debt / Equity = 0.61 (Debt 29.70b / totalStockholderEquity, last quarter 48.67b)
Debt / EBITDA = 1.21 (Net Debt 23.99b / EBITDA 19.83b)
Debt / FCF = 2.27 (Net Debt 23.99b / FCF TTM 10.57b)
Total Stockholder Equity = 45.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.38% (Net Income 10.22b / Total Assets 114.07b)
RoE = 22.68% (Net Income TTM 10.22b / Total Stockholder Equity 45.08b)
RoCE = 20.20% (EBIT 14.10b / Capital Employed (Equity 45.08b + L.T.Debt 24.71b))
RoIC = 16.65% (NOPAT 12.49b / Invested Capital 74.99b)
WACC = 6.54% (E(315.47b)/V(345.17b) * Re(7.02%) + D(29.70b)/V(345.17b) * Rd(1.59%) * (1-Tc(0.11)))
Discount Rate = 7.02% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 81.65 | Cagr: 0.03%
[DCF] Terminal Value 85.41% ; FCFF base≈9.25b ; Y1≈10.44b ; Y5≈14.10b
[DCF] Fair Price = 210.4 (EV 350.16b - Net Debt 23.99b = Equity 326.17b / Shares 1.55b; r=6.54% [WACC]; 5y FCF grow 14.89% → 3.0% )
EPS Correlation: 71.93 | EPS CAGR: 104.0% | SUE: N/A | # QB: 0
Revenue Correlation: 94.73 | Revenue CAGR: 8.57% | SUE: N/A | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.27 | Chg7d=-0.010 | Chg30d=-0.010 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=5.16 | Chg7d=-0.018 | Chg30d=-0.067 | Revisions Net=+1 | Growth EPS=+12.7% | Growth Revenue=+7.6%
EPS next Year (2027-12-31): EPS=5.96 | Chg7d=-0.005 | Chg30d=+0.035 | Revisions Net=+1 | Growth EPS=+15.6% | Growth Revenue=+6.0%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 7.9% - Earnings Yield 3.2%)
[Growth] Growth Spread = +1.3% (Analyst 6.0% - Implied 4.7%)
External Resources
Dataroma Stockcircle